BioStem Technologies to Present at Two Upcoming Investor Conferences
Rhea-AI Summary
BioStem Technologies (OTC:BSEM), a MedTech company specializing in placental-derived biologics for advanced wound care, has announced its participation in two upcoming investor conferences in New York.
The company will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 8, 2025, at 3:20 PM ET, followed by a presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 11:00 AM ET. Investors can access live and archived webcasts of both presentations through BioStem's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BSEM declined 7.55%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
POMPANO BEACH, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that Company management will present at the following upcoming investor conferences being held in New York, NY.
Morgan Stanley Global Healthcare Conference:
- Format: Fireside Chat
- Date: Monday, September 8, 2025
- Time: 3:20 PM ET
H.C. Wainwright 27th Annual Global Investment Conference:
- Format: Presentation
- Date: Tuesday, September 9, 2025
- Time: 11:00 AM ET
Interested parties may access live and archived webcasts of the presentations on the “investors” section of the Company’s website at: ir.biostemtechnologies.com.
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow us on X and LinkedIn.
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on Twitter and LinkedIn.
Contact BioStem Technologies, Inc.:
Website: www.biostemtechnologies.com
E-Mail: info@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342
Investor Relations:
Adam Holdsworth, BioStem Director of Investor Relations
E-Mail: adam@biostemtech.com
Phone: 917-497-9287
Or
Gilmartin Group
Philip Trip Taylor, Principal
E-Mail: philip@gilmartinir.com
Phone: 415-937-5406
FAQ
When is BioStem Technologies (BSEM) presenting at the Morgan Stanley Global Healthcare Conference 2025?
What is the format of BioStem's presentation at the H.C. Wainwright Conference 2025?
Where can investors watch BioStem Technologies' conference presentations?
What is BioStem Technologies' main business focus?
